NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/23/2022
Back to search
Official data from USPTO
P HLA PROTEIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
06/02/2023
Trademark type
Combined
Nice classes
1, 5, 42, 44
Filing date
10/13/2020
Registration date
08/23/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/23/2022
Last transaction
06/02/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/04/2021
First use in commerce
01/04/2021
Drawing code
3
Owner type
16
Owner location
Austin, TX
Examiner
MANGUBAT, ALEXANDER GEORGE
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a square on top with two squares on each side touching corners with one square on the bottom with the top left section missing and a floating square in the middle of the four squares forming the letter "P" next to the literal word "HLA Protein".
Holders and representatives
Holders
Pure Protein L.L.C.
Representatives
Ian W. Gillies KNOBBE, MARTENS, OLSON & BEAR, LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Reagents for scientificpharmaceuticalclinicalmedical research purposes; laboratory chemicalsprotein-based reagents used for the detection of antibodies and receptors in cellbloodtissue analysis for in vitro diagnostics for scientific use and research in the field of therapeutic reagent designs; chemicals and biochemicals in the nature of reactants and reagents for in vitro scientific or research use; chemicals and biochemicals for use in the manufacture of pharmaceutical preparations; chemicalbiochemical and biotechnological solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with antibody and B or T cell detectionseparation and labelling; biochemical reagents for detecting and analyzing molecules in protein arrays; diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; chemicalbiochemical and biotechnological products in the nature of reactants and reagents for use in biotechnological product development of therapeutics for the prevention and treatment of cancerinfectious diseasesautoimmune diseases and allergies; chemicalbiochemical and biotechnological preparations used in industry and sciencein the development and manufacture of pharmaceuticalspharmaceutical preparations and substancesfor the prevention and treatment of cancerinfectious diseasesautoimmune diseases and allergies; chemicalbiochemical and biotechnological preparations used in industry and sciencein the development and manufacture of pharmaceuticalspharmaceutical preparations and substancesfor the detectionprevention and treatment of rejection causing antibodiesB and T cells
Class 5
Chemicals and biochemicals for in vitro clinical and medical use
Class 42
Providing scientificpharmaceuticalclinicalmedical research information via the internet; research and development of new products; pharmaceutical drug and biomarker preparation target discoverydevelopmentvalidation in the nature of researchdevelopmentquality assurance services; pharmaceutical and scientific research and development services; medical research services; medical development services in the fields of pharmaceuticalsbiologychemistrybiochemistrybiotechnologyclinical trials; clinical research services in the fields of pharmaceuticalsbiologychemistrybiochemistryclinical trials; clinical development services in the nature of scientific development of clinical trials; consulting services in the field of pharmaceutical assessment; scientific and medical research consulting services for transplant and organ rejection assessment; validation in the nature of quality assurance servicesscreening and mapping in the nature of scientific research and development of biological material for drug discovery and vaccine manufacturing purposes; providing scientific information and medical research information in the fields of pharmaceuticalsbiologychemistrybiochemistrybiotechnologyclinical trials; scientific and medical research and development in the field of cancerinfectious diseasesautoimmune diseases and allergies; scientific and medical research and development in the field of antibodyB cell and T cell detection in transplant and organ rejection
Class 44
Medical consulting services for transplant and organ rejection assessment
Publications
History of USPTO decisions and trademark events.
28 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/23/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/16/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/15/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/23/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/23/2022
IUAF
USE AMENDMENT FILED
06/03/2022
EISU
TEAS STATEMENT OF USE RECEIVED
06/03/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/03/2022
EX1G
SOU EXTENSION 1 GRANTED
04/29/2022
EXT1
SOU EXTENSION 1 FILED
04/29/2022
EEXT
SOU TEAS EXTENSION RECEIVED
04/29/2022
DOCK
ASSIGNED TO EXAMINER
02/25/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/02/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/07/2021
PUBO
PUBLISHED FOR OPPOSITION
09/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/18/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/14/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/14/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/14/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/29/2021
GNRT
NON-FINAL ACTION E-MAILED
03/29/2021
CNRT
NON-FINAL ACTION WRITTEN
03/29/2021
DOCK
ASSIGNED TO EXAMINER
03/11/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
12/03/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/02/2020
NWAP
NEW APPLICATION ENTERED
10/16/2020
Continuous trademark protection
Get notified about every new filing that threatens P HLA PROTEIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.